Developer docs
API playgroundTry for free, no card

Search company profiles

Claria Medical

Full company profile

uuid0002bn2

Namestring
Claria Medical
Legal namestring
Claria Medical Inc.
Websiteurl
clariamedical.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Claria Medical is a U.S.-based medical device developer founded in 2017 and headquartered in Mountain View, California, focused on women's health surgical devices. The company's sole core product is The Claria System, an investigational device designed for safe extraction of an enlarged uterus during minimally invasive hysterectomy using a vaginal approach without a mini-laparotomy. The system combines a large-bore handpiece with integrated lighting and blade and a breach-resistant tissue containment container intended to reduce intraoperative container breach risk, eliminate abdominal incisions, and reduce procedure time variability and hospital readmissions.

The underlying technology is electromechanical rather than software-driven, with no AI/ML component disclosed. The company has validated its scientific approach through a $1 million NSF Phase II SBIR cooperative agreement (June 2022) for tissue containment development, an earlier NSF SBIR award of $256,000 (November 2020), and NIH grants covering hysterectomy, myomectomy, and related surgical procedures. Clinical evidence has been built through case reports at international investigator sites (Sydney Women's Endosurgery Centre, Hospital Angeles Morelia) and a 30-surgeon usability study presented at clinical conferences. As of the available data, the Claria System is limited by U.S. federal law to investigational use and is not available for commercial sale.

Claria Medical's business model is hardware sales of a Class II/III-style medical device to hospitals and gynecological surgery centers once FDA clearance is obtained. To date the company has been entirely grant- and strategic-capital-funded, having raised approximately $12.4 million cumulatively, including an $8 million strategic investment from Organon (January 2023) that includes an option to acquire the company. The Organon relationship effectively functions as both a capital source and a contingent commercialization channel. The go-to-market posture is enterprise field sales targeting hospital-based gynecological surgeons, supported by scientific conference engagement and a company website as primary demand-generation assets. Founder-led, with Alexey Salamini as co-founder and CEO and Steve Kim as co-founder and board member.

Short descriptiontext

Claria Medical is a pre-commercial women's health medical device developer building The Claria System, an investigational device for minimally invasive hysterectomy with a breach-resistant containment container. Founded in 2017 in Mountain View, California, the company targets hospitals and gynecological surgery centers and is currently funded by NSF and NIH grants and an $8M strategic investment from Organon.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive hysterectomy, women's health medical devices, tissue containment systems, gynecological surgical devices, investigational surgical devices
Industry2 codes
1Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy)
CodeHLAKAJAFPrimaryYes
2Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
CodeHLAHADAAPrimaryNo
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Women's Health Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Post-FDA Approval)
TypeHardware Sales
Description

Claria Medical is developing an investigational medical device (The Claria System) for minimally invasive hysterectomy. The company has not yet commercialized its product and is in the pre-revenue regulatory stage. Revenue is anticipated through device sales to hospitals and surgical centers upon FDA approval.

clariamedical.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Claria Medical is developing the Claria System, an investigational intelligent medical device for minimally invasive hysterectomy. The system enables safe extraction of an enlarged uterus using a vaginal approach without mini-laparotomy, featuring a large-bore handpiece with integrated lighting and blade, plus a breach-resistant tissue containment container. The product is not yet commercially available and is limited by U.S. federal law to investigational use pending FDA approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces container breach rates that risk hidden cancer spread or bowel injury
+3 more records
Product overview1 text field

Claria Medical is a medical device company with a single core product: The Claria System. The Claria System is an intelligent tissue containment and extraction device designed for minimally invasive hysterectomy procedures. It features redundant safety features for container breach resistance, integrated lighting and blade within a large-bore handpiece for rapid tissue extraction. The system aims to reduce patient risk, recovery time, and scarring by enabling vaginal extraction without mini-laparotomy. The product is currently investigational and not available for commercial sale.

Product and service1 record
1The Claria System
CategoryWomen's health medical device / Minimally invasive hysterectomy system
Description

Intelligent medical device system designed for safe extraction of an enlarged uterus using a vaginal approach with no mini-laparotomy, intended to minimize patient risk, recovery time, and scarring. Includes a large-bore handpiece with integrated lighting and blade and a breach-resistant tissue containment container with redundant safety features. Currently limited by U.S. federal law to investigational use and not available for commercial sale.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Claria Medical

Women's Health Medical Devicesclariamedical.com

Claria Medical is a pre-commercial women's health medical device developer building The Claria System, an investigational device for minimally invasive hysterectomy with a breach-resistant containment container. Founded in 2017 in Mountain View, California, the company targets hospitals and gynecological surgery centers and is currently funded by NSF and NIH grants and an $8M strategic investment from Organon.

What Claria Medical does

Claria Medical is a U.S.-based medical device developer founded in 2017 and headquartered in Mountain View, California, focused on women's health surgical devices. The company's sole core product is The Claria System, an investigational device designed for safe extraction of an enlarged uterus during minimally invasive hysterectomy using a vaginal approach without a mini-laparotomy. The system combines a large-bore handpiece with integrated lighting and blade and a breach-resistant tissue containment container intended to reduce intraoperative container breach risk, eliminate abdominal incisions, and reduce procedure time variability and hospital readmissions.

The underlying technology is electromechanical rather than software-driven, with no AI/ML component disclosed. The company has validated its scientific approach through a $1 million NSF Phase II SBIR cooperative agreement (June 2022) for tissue containment development, an earlier NSF SBIR award of $256,000 (November 2020), and NIH grants covering hysterectomy, myomectomy, and related surgical procedures. Clinical evidence has been built through case reports at international investigator sites (Sydney Women's Endosurgery Centre, Hospital Angeles Morelia) and a 30-surgeon usability study presented at clinical conferences. As of the available data, the Claria System is limited by U.S. federal law to investigational use and is not available for commercial sale.

Claria Medical's business model is hardware sales of a Class II/III-style medical device to hospitals and gynecological surgery centers once FDA clearance is obtained. To date the company has been entirely grant- and strategic-capital-funded, having raised approximately $12.4 million cumulatively, including an $8 million strategic investment from Organon (January 2023) that includes an option to acquire the company. The Organon relationship effectively functions as both a capital source and a contingent commercialization channel. The go-to-market posture is enterprise field sales targeting hospital-based gynecological surgeons, supported by scientific conference engagement and a company website as primary demand-generation assets. Founder-led, with Alexey Salamini as co-founder and CEO and Steve Kim as co-founder and board member.

Claria Medical firmographics

Firmographics
Name
Claria Medical
Legal name
Claria Medical Inc.
Website
https://clariamedical.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Claria Medical is a pre-commercial women's health medical device developer building The Claria System, an investigational device for minimally invasive hysterectomy with a breach-resistant containment container. Founded in 2017 in Mountain View, California, the company targets hospitals and gynecological surgery centers and is currently funded by NSF and NIH grants and an $8M strategic investment from Organon.
Ownership category
akta.pro rank

Claria Medical industry classification

Industry
Product category
Women's Health Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy) (HLAKAJAF)
akta.pro secondary industry
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

  • Minimally invasive hysterectomy
  • Women's health medical devices
  • Tissue containment systems
  • Gynecological surgical devices
  • Investigational surgical devices

Where Claria Medical is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Claria Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales (Post-FDA Approval): Claria Medical is developing an investigational medical device (The Claria System) for minimally invasive hysterectomy. The company has not yet commercialized its product and is in the pre-revenue regulatory stage. Revenue is anticipated through device sales to hospitals and surgical centers upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Claria Medical product offering

Product offering

Core offering

Claria Medical is developing the Claria System, an investigational intelligent medical device for minimally invasive hysterectomy. The system enables safe extraction of an enlarged uterus using a vaginal approach without mini-laparotomy, featuring a large-bore handpiece with integrated lighting and blade, plus a breach-resistant tissue containment container. The product is not yet commercially available and is limited by U.S. federal law to investigational use pending FDA approval.

Product overview

Claria Medical is a medical device company with a single core product: The Claria System. The Claria System is an intelligent tissue containment and extraction device designed for minimally invasive hysterectomy procedures. It features redundant safety features for container breach resistance, integrated lighting and blade within a large-bore handpiece for rapid tissue extraction. The system aims to reduce patient risk, recovery time, and scarring by enabling vaginal extraction without mini-laparotomy. The product is currently investigational and not available for commercial sale.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Claria System Intelligent medical device system designed for safe extraction of an enlarged uterus using a vaginal approach with no mini-laparotomy, intended to minimize patient risk, recovery time, and scarring. Includes a large-bore handpiece with integrated lighting and blade and a breach-resistant tissue containment container with redundant safety features. Currently limited by U.S. federal law to investigational use and not available for commercial sale.

Quantifiable outcome

  • Reduces container breach rates that risk hidden cancer spread or bowel injury
  • +3 more outcomes

Companies that use Claria Medical

Customer profile

Segments2 records

Ideal customer profiles1 record

Claria Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Claria Medical partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Claria Medical competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Claria Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Claria Medical leadership team

Management profile

Number of profiles

Profiles2 records

Claria Medical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Claria Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Claria Medical

What does Claria Medical do?

Claria Medical is developing the Claria System, an investigational intelligent medical device for minimally invasive hysterectomy. The system enables safe extraction of an enlarged uterus using a vaginal approach without mini-laparotomy, featuring a large-bore handpiece with integrated lighting and blade, plus a breach-resistant tissue containment container. The product is not yet commercially available and is limited by U.S. federal law to investigational use pending FDA approval.

Is Claria Medical a public or private company?

Claria Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Claria Medical founded?

Claria Medical was founded in 2017. It employs 11 to 50 people.

Where is Claria Medical based?

Claria Medical is headquartered in San Francisco, United States, in the North America region.

How does Claria Medical make money?

One revenue line is on record: medical Device Sales (Post-FDA Approval).

Does Claria Medical have an API?

No public API is recorded for Claria Medical.

What industry is Claria Medical in?

Claria Medical's product category is Women's Health Medical Devices. Its primary akta.pro industry code is HLAKAJAF, Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedicaldesignandoutsourcingThis de novo minimally invasive system was designed for safer hysterectomiesClaria Medical received FDA de novo classification in July 2026 for its minimally invasive hysterectomy system. The system includes a SafeStop feature that stops blade rotation on contact with a metallic container layer to prevent organ injury. The FDA added contraindications for suspected malignancy and a boxed warning about cancer risk.YahooClaria Medical secures FDA De Novo classification for hysterectomy deviceClaria Medical has received FDA De Novo classification and marketing authorization for its Claria system, a device designed to support tissue extraction during minimally invasive hysterectomy procedures. The FDA reviewed the device under its Safer Technologies Program, which aims to accelerate assessment of technologies expected to improve safety over existing options. The company plans to establish commercial pilot sites with prominent US healthcare systems following this authorization.Medical Device NetworkClaria Medical secures FDA De Novo classification for hysterectomy deviceClaria Medical has received FDA De Novo classification and marketing authorization for its Claria system, a tissue extraction device designed for minimally invasive hysterectomy procedures. The device uses SafeStop technology featuring a tri-layer tissue container and enables transvaginal tissue extraction, avoiding the need for mini-laparotomy, with clinical studies showing a median extraction time of four minutes for large uteri. The company plans to establish commercial pilot sites with US healthcare systems following the authorization and will present detailed clinical results later this year.MassDeviceClaria Medical earns FDA nod for tissue containment, removal device for hysterectomyClaria Medical announced it received FDA de novo authorization for its Claria system, an integrated tissue containment and removal device designed for minimally invasive hysterectomies. The device, which features SafeStop technology with electronic communication between its tri-layer container and handpiece, demonstrated a median extraction time of four minutes in clinical studies. This marks the first integrated tissue containment and removal system cleared by the FDA, which authorized the device through its Safer Technologies Program (STeP) that expedites review of devices improving treatment safety.Mpo-magFDA OKs Claria Medical's Tissue Containment & Removal System for HysterectomyThe FDA granted de novo classification and marketing authorization to Claria Medical's tissue containment and removal system for hysterectomies. The system, using SafeStop technology, achieved a median extraction time of four minutes for large uteri in a clinical study. Claria expects to release detailed results later this year.BioSpaceFDA Grants De Novo Classification to Claria Medical for Device Designed to Improve Safety and Efficiency of Hysterectomy ProceduresClaria Medical received FDA De Novo classification for its Claria System, an integrated tissue containment and removal device for hysterectomies. The system's clinical study showed a median extraction time of four minutes, with SafeStop technology preventing barrier breaches. The company plans to present detailed study data later this year.OrganonOrganon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive HysterectomyOrganon announced a strategic investment of $8 million in Claria Medical, granting the healthcare company an option to acquire the medical device developer. The investment supports the development of Claria's investigational uterine containment system for minimally invasive hysterectomies, which has received FDA Safer Technologies Program designation.NSFNSF Award SearchThe National Science Foundation awarded CLARIA MEDICAL, INC. a $1 million SBIR Phase II grant to develop a novel tissue containment and removal system for laparoscopic hysterectomies and myomectomies. The project aims to make these minimally invasive surgeries safer, faster, and more cost-effective by reducing morbidity risks and healthcare costs. The award covers the period from June 2022 to May 2026.SecSEC FORM DClaria Medical, Inc. filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The company raised a total of $4,469,158 from 59 investors in this equity offering.